PDF icon Download PDF
Thromb Haemost 1994; 72(01): 132-139
DOI: 10.1055/s-0038-1648824
Original Article
Schattauer GmbH Stuttgart

Adenosine Nucleotides and Serotonin Stimulate von Wille-brand Factor Release from Cultured Human Endothelial Cells

D S Palmer
1   The Ottawa Centre, Canadian Red Cross Society, Blood Transfusion Service, Ottawa, Ontario, Canada
,
M T Aye
2   National Office, Canadian Red Cross Society, Blood Transfusion Service, Ottawa, Ontario, Canada
3   The Depts. of Medicine, Faculty of Medicine, University of Ottawa, Ontario, Canada
,
P R Ganz
1   The Ottawa Centre, Canadian Red Cross Society, Blood Transfusion Service, Ottawa, Ontario, Canada
4   Depts. of Biochemistry, Faculty of Medicine, University of Ottawa, Ontario, Canada
,
M Halpenny
1   The Ottawa Centre, Canadian Red Cross Society, Blood Transfusion Service, Ottawa, Ontario, Canada
,
S Hashemi
2   National Office, Canadian Red Cross Society, Blood Transfusion Service, Ottawa, Ontario, Canada
3   The Depts. of Medicine, Faculty of Medicine, University of Ottawa, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 04 August 1993

Accepted after revision 02 March 1994

Publication Date:
26 July 2018 (online)

 PDF Download  Permissions and Reprints
Preview

Summary

Endothelial cells (ECs) synthesize and release von Willebrand factor (vWf) either constitutively or from Weibel-Palade bodies by a regulated pathway. Although stimulated release of vWf from ECs occurs following exposure to thrombin, histamine, interleukin, tissue necrosis factor and fibrin in vitro, these agents are unlikely to be present in physiologically relevant concentrations during the initial stages of primary hemostasis. Alternatively, agents known to be released from the dense granules of activated platelets at the sites of vascular injury may provide the initial physiological stimuli for vWf release from ECs in vivo. We have examined the effects of the platelet secretagogues ADP, AMP, ATP and serotonin on the release of vWf from ECs and demonstrated enhanced release in all cases. The extent and time at which optimum vWf release was observed depended on the agonist and its concentration. At 3 nM, optimum release occurred after 4 hours with ADP (330 %/ml) or 1 h with AMP (153%/ml) or ATP (450%/ml). At 30 nM, optimum release was seen after 1 hour with ADP (315 %/ml) or AMP (595%/ml) and after 15 min with ATP (938%/ml). With serotonin, optimal release was seen by 30 min at 0.3 μM (1034%/ml) and after 1 h at 1 pM (745%/ml) although the response after 15 min was nearly equivalent (667%/ml). The doses giving 50% of maximal response (ED50) after 1 h were 6.5 nM (ADP), 15.2 nM (AMP) and 2.4 nM (ATP) and 20 nM for ATP or 75 nM for serotonin after 15 or 30 min respectively. ADP also enhanced PGI2 release from ECs in a dose- and time-dependent manner. These observations support a mechanism whereby activated platelets, which interact with and bind to ECs or subendothelium and release adenine nucleotides or serotonin from platelet dense granules, could stimulate the release of vWf from adjacent ECs thereby enhancing EC-platelet interactions and facilitating primary hemostasis.